China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2015 - 2025)
China Pharma Holdings (CPHI) posted Asset Writedowns and Impairment of -$507897.0 for Q4 2025, down 2107.34% on a QoQ basis from $25302.0 in Q3 2025, and down 10.83% year-over-year from -$569559.2 in Q4 2024.
China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2015 - 2025) Analysis & Trends
China Pharma Holdings' Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at -$507897.0 for Q4 2025.
- Quarterly Asset Writedowns and Impairment fell 10.83% year-over-year to -$507897.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$267184.0 (up 41.09% YoY) and the FY2025 annual result came in at -$1018.0, down 117.85% from the prior year.
- Asset Writedowns and Impairment was -$507897.0 for Q4 2025 at China Pharma Holdings, down from $25302.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $213379.0 in Q1 2025 and bottomed at -$507897.0 in Q4 2025.
- A 5-year average of -$50769.3 and a median of -$3212.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment sank 2924.19% — and 2025, when it jumped 10428.12%.
- China Pharma Holdings' Asset Writedowns and Impairment stood at -$250622.0 in 2021, then surged by 95.96% to -$10136.0 in 2022, then surged by 260.09% to $16227.0 in 2023, then sank by 2924.19% to -$458282.0 in 2024, then decreased by 10.83% to -$507897.0 in 2025.
- Business Quant data shows CPHI's Asset Writedowns and Impairment at -$507897.0 in Q4 2025, $25302.0 in Q3 2025, and $2032.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -507,897.00 |
| Dec 31, 2025 | -507,897.00 |
| Sep 30, 2025 | 25,302.00 |
| Sep 30, 2025 | 25,302.00 |
| Jun 30, 2025 | 2,032.00 |
| Jun 30, 2025 | 2,032.00 |
| Mar 31, 2025 | 213,379.00 |
| Mar 31, 2025 | 213,379.00 |
| Dec 31, 2024 | -458,282.00 |
| Dec 31, 2024 | -458,282.00 |
| Sep 30, 2024 | -1,656.00 |
| Sep 30, 2024 | -1,656.00 |
| Jun 30, 2024 | 8,476.00 |
| Jun 30, 2024 | 8,476.00 |
| Mar 31, 2024 | -2,066.00 |
| Mar 31, 2024 | -2,066.00 |
| Dec 31, 2023 | 16,227.00 |
| Dec 31, 2023 | 16,227.00 |
| Sep 30, 2023 | -18,212.00 |
| Sep 30, 2023 | -18,212.00 |